Home › Multiple Myeloma › Connecticut

Pag-aaral pangklinika para sa Multiple Myeloma sa Connecticut

18 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa Connecticut.

Mga Lungsod sa Connecticut

Opisyal na teksto ng pag-aaral (English)

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site, New Haven

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07391657

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

University of Connecticut Health Center, Farmington

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07518186

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Yale University School Of Medicine, New Haven

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06500884

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

University of Connecticut Health Center, Farmington
Yale Cancer Center, New Haven

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07258511

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

University of Connecticut, Farmington
Yale New Haven Hospital, New Haven

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05552222

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Saint Vincent's Medical Center (SVMC), Bridgeport
Hartford Hospital, Hartford
Midstate Medical Center (MSMC), Meriden
at 4 pa

Nagre-recruitPhase 2

Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02693535

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Smilow Cancer Hospital-Derby Care Center, Derby
Smilow Cancer Hospital Care Center - Guilford, Guilford
Yale University, New Haven
at 1 pa

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06465316

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Smilow Cancer Center At Yale-New Haven /ID# 272447, New Haven

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06953960

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Yale University, New Haven

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07555938

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Yale New Haven Hospital-Smilow Cancer Center, New Haven

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06988488

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

GSK Investigational Site, Norwich

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT07227311

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Smilow Cancer Hospital-Derby Care Center, Derby
Smilow Cancer Hospital Care Center-Fairfield, Fairfield
Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
at 11 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04566328

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, New Haven

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT07764978

Integrated Cancer Repository for Cancer Research

Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Smilow Cancer Hospital-Derby Care Center, Derby
Smilow Cancer Hospital Care Center-Fairfield, Fairfield
Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
at 11 pa

Nagre-recruitPhase 3

Lahat ng edad · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT05561387

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Yale New Haven Hospital, New Haven

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT05243797

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Yale University, New Haven

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update May 13, 2026 · NCT06993675

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Yale Cancer Center, New Haven

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 18, 2026 · NCT06153251

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.